Abstract
Obstructive sleep apnoea (OSA) and hyperaldosteronism are very common in subjects with resistant hypertension. We hypothesized that aldosterone-mediated chronic fluid retention may influence OSA severity in patients with resistant hypertension. We tested this in an open-label evaluation by assessing the changes in the severity of OSA in patients with resistant hypertension after treatment with spironolactone. Subjects with resistant hypertension (clinical blood pressure (BP) ⩾140/90 mm Hg on ⩾3 antihypertensive medications, including a thiazide diuretic and OSA (defined as an apnoea–hypopnoea index (AHI) ⩾15) had full diagnostic, polysomnography before and 8 weeks after spironolactone (25–50 mg a day) was added to their ongoing antihypertensive therapy. In all, 12 patients (mean age 56 years and body mass index 36.8 kg m–2) were evaluated. After treatment with spironolactone, the AHI (39.8±19.5 vs 22.0±6.8 events/h; P<0.05) and hypoxic index (13.6±10.8 vs 6.7±6.6 events/h; P<0.05), weight and clinic and ambulatory BP were significantly reduced. Plasma renin activity (PRA) and serum creatinine were significantly higher. This study provides preliminary evidence that treatment with a mineralocorticoid receptor antagonist substantially reduces the severity of OSA. If confirmed in a randomized assessment, it will support aldosterone-mediated chronic fluid retention as an important mediator of OSA severity in patients with resistant hypertension.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M et al. High prevalence of unrecognized sleep apnea in drug resistant hypertension. J Hypertens 2001; 19: 2271–2277.
Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA . Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453–459.
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weismann P . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892–896.
Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC . Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699–705.
Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr . Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349–352.
Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP . Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217–2226.
Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S et al. Characterization of resistant hypertension - association between resistant hypertension, aldosterone and persistant intravascular volume expansion. Arch Int Med 2008; 168: 1159–1164.
Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007; 62: 868–872.
Bucca CB, Brssino L, Battisti A, Mutani R, Rolla G, Mangiardi L et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132: 440–446.
Rechtschaffen A, Kales A . A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Sleep. Brain Information Service/ Brain Research Institute, UCLA: Los Angeles, CA, 1968.
Kapa S, Sert Kuniyoshi FH, Somers VK . Sleep apnea and hypertension: interaction and implications for management. Hypertension 2008; 51: 605–608.
Hedner J, Darpo B, Ejnell H . Reduction in sympathetic activity after long-term CPAP treatment in sleep apnea: cardiovascular implications. Eur Respir J 1995; 8: 222–229.
Schulz R, Mahmoudi S, Hattar K . Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000; 162: 566–570.
IP MS, Lam B, Chan LY . Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162: 2166–2171.
Demaika TA, Kinasewitz GT, Tawk MM . Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea. J Clin Sleep Med 2009; 5: 103–107.
Calhoun DA, Nishizaka MK, Zaman MA, Harding SM . Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125: 112–117.
Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP . Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999; 131: 485–491.
Hanly PJ, Perratos A . Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 2–107.
Tang SC, Lam B, Ku PP, Leung WS, Chu CM, Ho YW et al. Alleviation of sleep apnea in patients with chronic renal failure by nocturnal cycler-assisted peritoneal dialysis compared with conventional continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2607–2616.
Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–165.
Rossi GP, Bernini G, Calliumi C, Desideri G, Fabris B, Ferri C et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–2300.
Shahar E, Whitnet CW, Redline S . Sleep disordered breathing and cardiovascular disease cross sectional results of the sleep heart health study. Am J Respir Crit Care Med 2001; 163: 19–25.
Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V . Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034–2041.
Marin JM, Carrizo SJ, Vicente E, Agusti AGN . Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046–1053.
Acknowledgements
This study was supported by NHLBI SCCOR P50 HL077100 (DAC), RO1-HL79040 (DAC), T32 HL007457 (KG) and GCRC Grant M01-RR00032. We thank David Moore, Melissa Butler, and Louise Dover, for assistance in conducting the overnight sleep studies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gaddam, K., Pimenta, E., Thomas, S. et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 24, 532–537 (2010). https://doi.org/10.1038/jhh.2009.96
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2009.96
Keywords
This article is cited by
-
Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism
Hypertension Research (2024)
-
Obstructive Sleep Apnea and Hypertension: Updates to a Critical Relationship
Current Hypertension Reports (2022)
-
Effect of antihypertensive medications on sleep status in hypertensive patients
Sleep and Biological Rhythms (2022)
-
Obstructive sleep apnea syndrome–related hypertension and sarcopenia: a brief glance on the renin-angiotensin-aldosterone system
Sleep and Breathing (2021)
-
Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases: A Consensus Document by the Italian Society of Hypertension (SIIA)
High Blood Pressure & Cardiovascular Prevention (2021)